Market research
PMRA.F Pharma Mar, S.A
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 25.59
- Analyst target
- Not available
- Dividend yield
- 1.2%
- Beta
- 0.43
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- ES0169501022
- Market cap
- 1B
- P/E ratio
- 25.59
- Analyst target
- Not available
- Dividend yield
- 1.2%
- Beta
- 0.43
About
About Pharma Mar, S.A
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PMRA.F discussion.
5 years, 4 months ago
Pharma Mar, S.A is currently in a long term downtrend where the price is trading 17.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.3.
Pharma Mar, S.A's total revenue rose by 127.2% to $53M since the same quarter in the previous year.
Its net income has increased by 10.9% to $17M since the same quarter in the previous year.
Finally, its free cash flow grew by 450.1% to $9M since the same quarter in the previous year.
Based on the above factors, Pharma Mar, S.A gets an overall score of 4/5.